Some (translated) sections from it: "...the company's core product FebriDx and COVID-19 testing product CoviDx are expected to be approved by the US FDA in the next 1-2 months and are expected to be included in the reimbursement system, thus officially opening the door to the US medical testing market and accelerating corporate revenue growth."
"In 2020, the global sales market of diagnostic tests for rapid detection equipment is 29.6 billion U.S. dollars. The North American and European markets together account for approximately 64% of the global market share. Among them, the total potential market value of rapid diagnostic tests for identifying infectious diseases is estimated to be 1.8 billion U.S. dollars. This means that Lumos, which focuses on the European and American markets, will have a significant increase in demand for commercial services and POC testing products driven by the Covid-19 epidemic, which is good for future business development."
"According to AFR reports, in October last year, Lumos was "snatched" by institutions in its Pre-IPO round of A$25 million in financing, and it was oversubscribed.However, this IPO is no exception. Australia's top investment companies, including Australia's top IPO funds Perennial, Ellerston, Washington H Soul Pattinson and Australian Unity's healthcare fund as cornerstone investors, subscribe for more than 70% of the IPO share.In addition, the amount of investment purchased by many investment institutions has been greatly reduced, less than 20% of the amount of purchase, and the purchase channel was closed early due to oversubscription. All these fully confirm Lumos' enthusiasm in the capital market."
"From fiscal year 2018 to fiscal year 2021, the compound annual revenue growth rate was 109%."
LDX Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
